U.S. markets open in 7 hours 16 minutes
  • S&P Futures

    3,764.75
    -0.75 (-0.02%)
     
  • Dow Futures

    30,873.00
    -5.00 (-0.02%)
     
  • Nasdaq Futures

    12,441.25
    -13.75 (-0.11%)
     
  • Russell 2000 Futures

    2,144.90
    +0.40 (+0.02%)
     
  • Crude Oil

    64.85
    +1.02 (+1.60%)
     
  • Gold

    1,694.90
    -5.80 (-0.34%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1959
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.5500
    0.0000 (0.00%)
     
  • Vix

    28.57
    +1.90 (+7.12%)
     
  • GBP/USD

    1.3881
    -0.0013 (-0.09%)
     
  • USD/JPY

    108.2600
    +0.2840 (+0.26%)
     
  • BTC-USD

    47,421.52
    -2,327.75 (-4.68%)
     
  • CMC Crypto 200

    949.84
    -37.37 (-3.79%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Cantor Fitzgerald Recaps Aurora Cannabis' Q2 Report: 'Trends Are Encouraging'

  • Oops!
    Something went wrong.
    Please try again later.
Jayson Derrick
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors should continue sticking to the sidelines when it comes to Aurora Cannabis Inc (NYSE: ACB).

That's according to a Cantor Fitzgerald analyst, citing the sales and EBITDA miss in the cannabis company's most recent earnings report.

The Aurora Cannabis Analyst: Cantor analyst Pablo Zuanic maintains a Neutral rating on Aurora's TSX-listed stock with a price target lifted from C$17 to C$18.

The Aurora Cannabis Thesis: Aurora reported total net cannabis sales of C$67.7 million that were 2% shy of consensus estimates while EBITDA of C$-16.8 million missed expectations of C$-5.5 million, Zuanic wrote in a note.

Despite falling short, revenue was "at least better than we had expected" and EBITDA loss as a percentage of sales improved from -85% in the prior quarter to -25%.

Related Link: Aurora Posts Q2 Earnings, Touts 562% Spike In 'International Medical' Cannabis Sales

The company still has a long way to go before break-even EBITDA although the earnings report suggests a path towards higher margins, the analyst wrote.

Aurora's shift to derivative products and premium flower along with growth in the profitable international business bodes well for growth prospects.

"We realize the stock market context is volatile, but all else being equal, we think trends are encouraging for ACB," Zuanic added. "Also, in relative terms, ACB is
attractively valued, although given the recent run-up in Canadian stocks, we realize this is not saying much."

ACB Price Action: Shares of NYSE-listed Aurora Cannabis were trading lower by more than 7% Friday morning at $13.36.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.